ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
BioEclipse Announces First Patient Dosed in CRX100 Trial for Refractory Solid Tumors
March 10, 2021BioEclipse Therapeutics™ announced the administration of the first dose of CRX100 to a volunteer in the ongoing Phase 1 clinical trial in patients with refractory solid tumors. -
BioEclipse Initiates Enrollment in Phase 1 Dose-Escalation Trial for Solid Tumors
December 22, 2020BioEclipse Therapeutics™ announced the initiation of patient enrollment in a Phase 1 dose-escalation trial to treat refractory solid tumors. -
BioEclipse Receives FDA Clearance of CRX100 IND Application
April 30, 2020BioEclipse Therapeutics announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the Company's lead drug candidate, CRX100.
Pharma Sources Insight January 2025
